Senzime AB (SEZI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-23.03 Million ≈ $-2.48 Million USD) by net assets (Skr283.50 Million ≈ $30.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SEZI stock market capitalisation for the company's overall valuation and market capitalisation.
Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Senzime AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency. See debt repayment capacity of Senzime AB to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Latitude Tree Holdings Bhd
KLSE:7006
|
0.021x |
|
Shareholder Value Beteiligungen AG
XETRA:SVE
|
0.043x |
|
Deswell Industries Inc
NASDAQ:DSWL
|
0.027x |
|
Unick Corporation
KQ:011320
|
0.105x |
|
Aarti Surfactants Limited
NSE:AARTISURF
|
0.091x |
|
Innventure, Inc.
NASDAQ:INV
|
-0.050x |
|
Southern Rubber Industry JSC
VN:CSM
|
0.143x |
|
Zegona Communications Plc
LSE:ZEG
|
-0.535x |
Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)
The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. View Senzime AB stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr304.46 Million ≈ $32.76 Million |
Skr-109.10 Million ≈ $-11.74 Million |
-0.358x | -16.98% |
| 2024-12-31 | Skr345.86 Million ≈ $37.22 Million |
Skr-105.94 Million ≈ $-11.40 Million |
-0.306x | -0.97% |
| 2023-12-31 | Skr375.48 Million ≈ $40.41 Million |
Skr-113.91 Million ≈ $-12.26 Million |
-0.303x | +41.91% |
| 2022-12-31 | Skr261.90 Million ≈ $28.18 Million |
Skr-136.78 Million ≈ $-14.72 Million |
-0.522x | +3.31% |
| 2021-12-31 | Skr150.58 Million ≈ $16.20 Million |
Skr-81.33 Million ≈ $-8.75 Million |
-0.540x | -225.94% |
| 2020-12-31 | Skr231.35 Million ≈ $24.90 Million |
Skr-38.34 Million ≈ $-4.13 Million |
-0.166x | +0.04% |
| 2019-12-31 | Skr163.69 Million ≈ $17.62 Million |
Skr-27.14 Million ≈ $-2.92 Million |
-0.166x | -56.49% |
| 2018-12-31 | Skr167.41 Million ≈ $18.02 Million |
Skr-17.73 Million ≈ $-1.91 Million |
-0.106x | -21.04% |
| 2017-12-31 | Skr140.46 Million ≈ $15.12 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.088x | -15.36% |
| 2016-12-31 | Skr131.87 Million ≈ $14.19 Million |
Skr-10.00 Million ≈ $-1.08 Million |
-0.076x | +45.81% |
| 2015-12-31 | Skr45.81 Million ≈ $4.93 Million |
Skr-6.41 Million ≈ $-690.18K |
-0.140x | -60.40% |
| 2014-12-31 | Skr44.08 Million ≈ $4.74 Million |
Skr-3.85 Million ≈ $-414.05K |
-0.087x | +39.78% |
| 2013-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-5.43 Million ≈ $-584.31K |
-0.145x | +23.55% |
| 2012-12-31 | Skr31.99 Million ≈ $3.44 Million |
Skr-6.06 Million ≈ $-652.57K |
-0.190x | -170.80% |
| 2011-12-31 | Skr27.87 Million ≈ $3.00 Million |
Skr-1.95 Million ≈ $-209.94K |
-0.070x | +27.67% |
| 2010-12-31 | Skr21.90 Million ≈ $2.36 Million |
Skr-2.12 Million ≈ $-228.10K |
-0.097x | -0.30% |
| 2009-12-31 | Skr16.61 Million ≈ $1.79 Million |
Skr-1.60 Million ≈ $-172.54K |
-0.096x | -664.63% |
| 2006-12-31 | Skr7.55 Million ≈ $812.29K |
Skr129.00K ≈ $13.88K |
0.017x | -- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more